Oncology drug developer Chordia Therapeutics has raised series A funding from backers including Kyoto University Innovation Capital.

Kyoto University Innovation Capital, the investment arm of Kyoto University, has invested in a series A round of undisclosed size for Japan-based oncology drug developer Chordia Therapeutics, Fierce Biotech reported yesterday.

Pharmaceutical firm Takeda, which has licensed several drug programs to Chordia, also invested, as did Mitsubishi UFJ Capital and SMBC Venture Capital, the venture capital arms of banks Mitsubishi UFJ Financial Group and Sumitomo Mitsui Banking Corporation.

Kyoto University Innovation Capital took part in the round through its link…